Clinical Trials Browser

Everolimus × Genitourinary × Clear all

NCT07405164 2026-03-31

MK-6482-043

Phase 3 Recruiting

Carcinoma, Renal Cell, von Hippel-Lindau Disease

NCT05012371 2026-03-05

Lenvatinib With Everolimus Versus Cabozantinib for Second-Line or Third-Line Treatment of Metastatic Renal Cell Cancer

Phase 2 Active not recruiting

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell

NCT04895748 2026-03-03

DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer & Other Malignancies

Phase 1 Terminated

CNSEndocrineGenitourinary

Hereditary leiomyomatosis and renal cell cancer, Carcinoma, Renal Cell, von Hippel-Lindau Disease, Paraganglioma, Pheochromocytoma

NCT02184416 2026-02-27

ADONIS

Carcinoma, Renal Cell

NCT02811861 2026-02-23

CLEAR

Phase 3 Active not recruiting

1,069 enrolled 12 charts 2 FDA

Carcinoma, Renal Cell

NCT01217931 2026-01-30

Sequential Two-agent Assessment in Renal Cell Carcinoma Therapy: The START Trial

Phase 2 Active not recruiting

Carcinoma, Renal Cell, Kidney Neoplasms

NCT07369505 2026-01-27

Sapu003 in Advanced mTOR-sensitive Solid Tumors

Phase 1 Recruiting

EndocrineGastrointestinalGenitourinaryNET

Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Tuberous Sclerosis, Neuroendocrine Tumors

NCT01120249 2025-09-16

S0931

Phase 3 Completed

1,545 enrolled 15 charts

Carcinoma, Renal Cell, Kidney Neoplasms

NCT01313559 2025-04-30

Pasireotide (SOM230) With or Without Everolimus in Treating Patients With Hormone Resistant, Chemotherapy Naive Prostate Cancer

Phase 2 Terminated

6 enrolled 10 charts

Prostatic Neoplasms

NCT04195750 2025-04-29

A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005)

Phase 3 Active not recruiting

755 enrolled 28 charts 2 FDA

Carcinoma, Renal Cell, Kidney Neoplasms

NCT03324373 2025-04-24

Lenvatinib and Everolimus in Renal Cell Carcinoma (RCC)

Phase 1 Completed

Carcinoma, Renal Cell

NCT03173560 2025-04-01

Trial to Assess Safety and Efficacy of Lenvatinib (18 mg vs. 14 mg) in Combination With Everolimus in Participants With Renal Cell Carcinoma

Phase 2 Completed

343 enrolled 25 charts

Carcinoma, Renal Cell

NCT05188118 2024-11-06

Rapid Sequencing of Approved Therapies in Patients with Metastatic or Unresectable Clear Cell Renal Cell Carcinoma

Phase EARLY_PHASE1 Recruiting

Carcinoma, Renal Cell, Neoplasm Metastasis

NCT00655655 2024-08-21

Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors

Phase 1 Completed

DermatologicEndocrineGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Glucagonoma, Insulinoma, Melanoma, Pheochromocytoma, Somatostatinoma, Carcinoma, Merkel Cell, Gastrinoma, Carcinoma, Islet Cell, Carcinoma, Medullary

NCT06317298 2024-03-19

Fruquintinib Plus Everolimus as 2nd Line Therapy of ccRCC Patients Progressed Post IO and TKI Therapy

Phase NA Unknown

Carcinoma, Renal Cell

NCT03878524 2024-03-04

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Phase 1 Terminated

BreastClassical hematologyGastrointestinalGenitourinaryLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Blast Crisis, Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Thrombocytosis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

NCT06211790 2024-01-18

Proteomic Guided First-line Precision Treatment of Renal Clear Cell Carcinoma

Phase 2 Recruiting

Carcinoma, Renal Cell, Kidney Neoplasms

NCT01215136 2023-11-24

First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma

Phase 2 Terminated

36 enrolled 14 charts

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT02599324 2023-11-18

Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors

Phase 1/2 Completed

263 enrolled 34 charts

Carcinoma, Renal Cell

NCT02106507 2023-05-26

ARN 509 Plus Everolimus in Men With Progressive Metastatic Castration-Resistant Prostate Cancer After Treatment With Abiraterone Acetate

Phase 1 Completed

Prostatic Neoplasms

NCT02890069 2023-01-11

A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat

Phase 1 Completed

BreastGastrointestinalGenitourinaryThoracic

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT00805129 2022-11-25

Everolimus (RAD001) in Metastatic Transitional Cell Carcinoma of the Urothelium

Phase 2 Completed

46 enrolled 11 charts

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT00830895 2022-11-09

RAD001 for Non-clear Cell Renal Cell Carcinoma (RCC)

Phase 2 Completed

Carcinoma, Renal Cell, Neoplasm Metastasis

NCT03163667 2022-09-15

ENTRATA

Phase 2 Completed

69 enrolled 12 charts

Carcinoma, Renal Cell

NCT01582009 2022-08-15

Panobinostat and Everolimus in Treating Patients With Metastatic or Unresectable Renal Cell Cancer That Does Not Respond to Treatment With Sunitinib Malate or Sorafenib Tosylate

Phase 1/2 Terminated

26 enrolled 11 charts

Carcinoma, Renal Cell

NCT01668784 2022-08-09

Study of Nivolumab (BMS-936558) vs. Everolimus in Pre-Treated Advanced or Metastatic Clear-cell Renal Cell Carcinoma (CheckMate 025)

Phase 3 Completed

821 enrolled 18 charts

Carcinoma, Renal Cell, Neoplasm Metastasis

NCT02071862 2022-07-20

Study of the Glutaminase Inhibitor CB-839 in Solid Tumors

Phase 1 Completed

BreastGenitourinaryOther solid neoplasmThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Mesothelioma, Triple Negative Breast Neoplasms

NCT01034631 2022-07-11

BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma

Phase 1/2 Completed

154 enrolled 22 charts

Carcinoma, Renal Cell, Kidney Neoplasms

NCT00392821 2022-06-06

Dosing and Effectiveness Study of Sorafenib and RAD001 in the Treatment of Patients With Advanced Kidney Cancer

Phase 1/2 Completed

78 enrolled 11 charts

Kidney Neoplasms

NCT01399918 2022-02-01

Everolimus and Bevacizumab in Advanced Non-Clear Cell Renal Cell Carcinoma (RCC)

Phase 2 Completed

57 enrolled 10 charts

Carcinoma, Renal Cell

NCT01218555 2022-01-27

Study of Everolimus (RAD001) in Combination With Lenalidomide

Phase 1 Completed

44 enrolled 9 charts

EndocrineGenitourinaryNET

Kidney Neoplasms, Neuroendocrine Tumors

NCT05124431 2021-11-18

ALTER-UC-001

Phase 2 Unknown

Carcinoma, Renal Cell

NCT02125084 2021-05-04

Enzalutamide Plus Everolimus in Men With Metastatic Castrate-Resistant Prostate Cancer

Phase 1 Completed

Prostatic Neoplasms

NCT01185366 2021-04-28

Everolimus Versus Sunitinib in Non-Clear Cell Renal Cell Carcinoma

Phase 2 Terminated

73 enrolled 17 charts

Carcinoma, Renal Cell, Kidney Neoplasms

NCT01865747 2021-04-27

METEOR

Phase 3 Completed

658 enrolled 15 charts

Carcinoma, Renal Cell

NCT00827359 2021-02-24

Biomarker Trial of Everolimus in Patients With Advanced Renal Cell Carcinoma

Phase 2 Completed

25 enrolled 13 charts

Carcinoma, Renal Cell, Kidney Neoplasms

NCT03095040 2021-02-08

CM082 Combined With Everolimus in Chinese Patients With Metastatic Renal Cell Carcinoma

Phase 3 Unknown

Renal Cell Cancer Metastatic

NCT01152801 2020-12-21

Safety of RAD001 in Chinese Patients With Metastatic Renal Cell Cancer

Phase 1 Completed

Carcinoma, Renal Cell

NCT01482156 2020-12-21

Dose Finding Study of RAD001 (Everolimus, Afinitor®) in Combination With BEZ235 in Patients With Advanced Solid Tumors

Phase 1 Completed

BreastGenitourinary

Breast Neoplasms, Carcinoma, Renal Cell

NCT02077933 2020-12-08

Study of Safety and Efficacy of Alpelisib With Everolimus or Alpelisib With Everolimus and Exemestane in Advanced Breast Cancer Patients, Renal Cell Cancer and Pancreatic Tumors

Phase 1 Completed

BreastGenitourinary

Breast Neoplasms, Carcinoma, Renal Cell, Kidney Neoplasms, Neoplasms

NCT01051570 2020-12-01

Carboplatin, Everolimus, and Prednisone in Treating Patients With Metastatic Prostate Cancer That Progressed After Docetaxel

Phase 2 Completed

26 enrolled 9 charts

Prostatic Neoplasms

NCT02187302 2020-05-28

CRLX101(NLG207) in Combination With Bevacizumab for Metastatic Renal Cell Carcinoma (mRCC) Versus Standard of Care (SOC)

Phase 2 Completed

Carcinoma, Renal Cell

NCT01239342 2019-10-10

Akt Inhibitor MK2206 or Everolimus in Treating Patients With Refractory Kidney Cancer

Phase 2 Terminated

43 enrolled 12 charts

Carcinoma, Renal Cell

NCT01184326 2019-10-02

Expanded Phase I Pazopanib and Everolimus in Advanced Solid Tumors and Previously Treated Advanced Urothelial Cancer

Phase 1 Completed

23 enrolled 16 charts

Kidney Neoplasms

NCT00976755 2019-08-09

Everolimus as First-Line Therapy in Treating Patients With Prostate Cancer

Phase 2 Completed

Prostatic Neoplasms

NCT01206764 2019-06-24

A Trial of Everolimis in Patients With Advanced Renal Cell Carcinoma.

Phase 4 Completed

143 enrolled 11 charts

Carcinoma, Renal Cell

NCT02504892 2019-03-22

Everolimus Therapy in People With Birt-Hogg-Dube Syndrome (BHD)-Associated Kidney Cancer or Sporadic Chromophobe Renal Cancer

Phase 2 Terminated

3 enrolled 7 charts

Kidney Neoplasms, Neoplastic Syndromes, Hereditary, Birt-Hogg-Dube Syndrome

NCT02454478 2019-03-19

Study of Lenvatinib in Combination With Everolimus in Participants With Unresectable Advanced or Metastatic Renal Cell Carcinoma (RCC)

Phase 1 Completed

7 enrolled 17 charts

Carcinoma, Carcinoma, Renal Cell

NCT01198158 2019-03-06

Everolimus With or Without Bevacizumab in Treating Patients With Advanced Kidney Cancer That Progressed After First-Line Therapy

Phase 3 Terminated

77 enrolled 11 charts

Carcinoma, Renal Cell

NCT01136733 2019-02-27

A Study of E7080 Alone, and in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Renal Cell Carcinoma Following One Prior Vascular Endothelial Growth Factor (VEGF)-Targeted Treatment

Phase 1/2 Completed

173 enrolled 28 charts

Carcinoma, Renal Cell